SOURCE: SuperSonic Imagine

SuperSonic Imagine

October 01, 2015 13:18 ET

SuperSonic Imagine Appoints Dr. Hermann Requardt as Supervisory Board Chairman

AIX-EN-PROVENCE, FRANCE--(Marketwired - Oct 1, 2015) - SuperSonic Imagine (EURONEXT PARIS: SSI) (FR0010526814, PEA-PME eligible), a company specializing in ultrasound medical imaging, announced today the appointment of Dr. Hermann Requardt, former Chief Executive Officer of Siemens Healthcare, as Chairman of its Supervisory Board. Dr. Requardt has been serving as an independent strategic advisor to the Supervisory Board since May 2015 and will, as expected, replace Mr. Bernard Doorenbos, who has been Acting Chairman since May 2015. Mr. Doorenbos will continue as a member of the Supervisory Board.

Tom Egelund, SuperSonic Imagine's Chief Executive Officer, comments: "We are delighted to welcome Dr. Requardt as the Chairman of the Supervisory Board. His successful experience at Siemens Healthcare, a leading player within the sector, represents an invaluable asset to the Company. Since May, he has been instrumental in providing superior short and medium-term guidance to SuperSonic Imagine and his significant knowledge of the Company sets the stage for a seamless transition to the Chairman of the Supervisory Board. We would like to thank Mr. Doorenbos for his complete commitment to his mission as Acting Chairman of our Supervisory Board and for his continued contributions to SuperSonic Imagine's development."

Dr. Requardt is an Honorary Professor of Physics at the Goethe University in Frankfurt and serves on several academic and industrial boards. He most recently served as Chief Executive Officer of Siemens Healthcare from 2009 to February 2015. Prior to that, he was Chief Technology Officer of Siemens AG since 2008. He began his career in 1984 as a physicist within Siemens Medical Solution's Imaging division. Dr. Requardt holds a Ph.D. in Biophysics, with a focus on radiation biophysics and microbiology, from the University of Frankfurt.

"I am honored to be appointed Chairman of SuperSonic Imagine's Supervisory Board as my substantial commitment and involvement with the Company over the last few months have further increased my belief in its innovative technology. I look forward to applying my industry expertise to help guide the company on the path to realize its growth potential and increase the adoption of its technology worldwide," commented Dr. Requardt.

About SuperSonic Imagine
Founded in 2005 and based in Aix-en-Provence (France), SuperSonic Imagine is a company specializing in medical imaging. The company designs, develops and markets a revolutionary ultrasound system, Aixplorer®, with an UltraFast™ platform that can acquire images 200 times faster than conventional ultrasound systems. Aixplorer® is the only system that can image two types of waves: ultrasound waves ensure excellent image quality and shear waves, which allow physicians to visualize and analyze the stiffness of tissue in a real-time, reliable, reproducible and non-invasive manner. This innovation, ShearWave™ Elastography, significantly improves the detection and characterization of numerous pathologies in several applications including breast, thyroid, liver and prostate. SuperSonic Imagine has been granted regulatory clearances for the commercialization of Aixplorer® in the main global markets. Over the past years, SuperSonic Imagine enjoyed the backing of several prestigious investors, among which Auriga Partners, Edmond de Rothschild Investment Partners, Bpifrance, Omnes Capital and NBGI.

For more information about SuperSonic Imagine, please go to www.supersonicimagine.com

Contact Information

  • SuperSonic Imagine
    Marketing & Communication
    Emmanuelle Vella
    Email Contact
    +33 4 86 79 03 27

    Blueprint Life Science Group
    Investor Relations - US
    Candice Knoll
    Email Contact
    +1 415 375 3340 Ext. #4

    NewCap
    Investor Relations - EU
    Pierre Laurent / Florent Alba
    Email Contact
    +33 1 44 71 98 55

    ComCorp
    Media Relations
    Adelaide Manester
    Email Contact
    +33 1 58 18 32 58